Allarity Therapeutics, INC. 8-K Filing
Ticker: ALLR · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001860657
Sentiment: neutral
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2026-04-01 08:54:39
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0279571-8k_allarity.htm (8-K) — 24KB
- ea027957101ex99-1.htm (EX-99.1) — 78KB
- ea027957101_ex99-1img1.jpg (GRAPHIC) — 3KB
- 0001213900-26-038061.txt ( ) — 281KB
- allr-20260331.xsd (EX-101.SCH) — 3KB
- allr-20260331_lab.xml (EX-101.LAB) — 33KB
- allr-20260331_pre.xml (EX-101.PRE) — 22KB
- ea0279571-8k_allarity_htm.xml (XML) — 3KB
02 Results
Item 2.02 Results of Operations and Financial Condition. On March 31, 2026, Allarity Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal year ended December 31, 2025. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated March 31, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: April 1, 2026 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer 2